Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
Sponsor: Imara, Inc.
Summary
This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.
Official title: An Open-label Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Who Participated in Study IMR-SCD-102
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2019-05-22
Completion Date
2025-03
Last Updated
2022-03-04
Healthy Volunteers
No
Conditions
Interventions
IMR-687
Oral administration of once daily IMR-687
Locations (7)
University of Connecticut Health Center
Farmington, Connecticut, United States
Foundation for Sickle Cell Disease Research
Hollywood, Florida, United States
Baylor Scott & White Medical Center - Temple
Temple, Texas, United States
Bristol Haematology and Oncology Centre
Bristol, United Kingdom
University College London Hospital NHS Foundation Trust
London, United Kingdom
Guy's and St Thomas Hospital CRF
London, United Kingdom
Royal London Hospital
London, United Kingdom